Implantable cardiac devices market seen reaching $20.33 billion by 2030

The implantable cardiac devices market is projected to grow from $13.34 billion in 2025 to $14.51 billion in 2026, with demand fueled by heart disease, aging populations and wider use of remote monitoring and AI-assisted diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - The implantable cardiac devices market is expanding as more patients need treatment for arrhythmias, heart failure and other cardiovascular conditions. - Growth in the category points to rising demand for devices that can monitor and regulate heart function over long periods. - The market also reflects broader adoption of remote monitoring, minimally invasive therapy and digital healthcare tools.

What happened: - The Business Research Company released its Implantable Cardiac Devices Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The market is projected to increase from $13.34 billion in 2025 to $14.51 billion in 2026. - The forecast implies a CAGR of 8.8%. - The market is expected to reach $20.33 billion by 2030 at the same CAGR. - A free sample of the market report is available. - The full implantable cardiac devices market report is also available.

The details: - Implantable cardiac devices are surgically inserted medical tools used to manage heart conditions, especially arrhythmias and heart failure. - These devices continuously monitor heart activity and can deliver electrical impulses to correct abnormal heartbeats. - Historical market growth has been supported by more patients with cardiac arrhythmias, an aging global population, better hospital cardiac care infrastructure, wider pacemaker adoption and more advanced implantable devices. - Future growth is expected to come from remote patient monitoring, minimally invasive cardiac therapies, digital healthcare integration, battery and lead innovation, and AI-assisted cardiac diagnostics. - Key trends expected through 2030 include miniaturized devices, stronger remote monitoring integration, more MRI-compatible implants, wider use of cardiac resynchronization therapy, and a focus on longer device life and higher reliability. - Heart disease growth is tied to unhealthy diets, sedentary lifestyles, obesity, diabetes, hypertension, aging populations and higher stress levels. - In May 2024, the Singapore Heart Foundation reported that ischemic heart disease caused 5,302 deaths, up from 5,290 deaths in 2022.

Between the lines: - The market forecast suggests device makers are shifting from basic implantable hardware toward connected, software-enabled cardiac care. - The emphasis on MRI compatibility, miniaturization and longer battery life signals competition around patient convenience and clinical utility, not just device volume. - North America held the largest market share in 2025, but faster growth in Asia-Pacific suggests the next demand wave may come from expanding healthcare access and rising cardiovascular burden outside the U.S. and Europe. - The report’s added market attractiveness scoring, TAM analysis, company scoring matrices and forecasting dashboards indicate a stronger focus on commercial planning and segment selection.

What's next: - The market is expected to keep growing through 2030 as hospitals and patients adopt more connected cardiac care. - Asia-Pacific is projected to post the fastest growth during the forecast period. - Continued innovation in monitoring, implant design and battery performance is likely to shape product competition. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Implantable cardiac devices are moving deeper into a growth phase driven by chronic disease, aging populations and smarter, more durable technology.